Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study

Cancer

Volumn 115, Issue 18, 2009, Pages 4110-4117

  Vaughn, David J ^a,b   Srinivas, Sandy ^c   Stadler, Walter M ^d   Pili, Roberto ^e   Petrylak, Daniel ^f   Sternberg, Cora N ^g   Smith, David C ^h   Ringuette, Sarah ⁱ   De Wit, Edwin ⁱ   Pautret, Virginie ⁱ   George, Claude ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

Platinum containing chemotherapy; Toxicity; Urothelial carcinoma; Vinflunine

Indexed keywords

PLATINUM; VINFLUNINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; ILEUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLATINUM COMPOUNDS; RETREATMENT; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 70149110433     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24460     Document Type: Article

References (15)

1. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, cisplatin, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-1073.
2. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
3. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608. (Pubitemid 46224062)
4. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69:62-79. (Pubitemid 46186484)
5. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol. 2006;24:5545-5551. (Pubitemid 46631335)
6. Iaffailoi RV, Milano A, Caponigro F. Therapy of metastatic bladder carcinoma. Ann Oncol. 2007;18(supp 6):vi153-vi156.
7. Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997;119:8576-8577. (Pubitemid 27404589)
8. Fahy J. Modifications in the "upper" velbanamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des. 2001;7:1181-1197.
9. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512-520.
10. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437-447. (Pubitemid 28140706)
11. Bonfil RD, Russo DM, Binda MM, et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002;7:159-166. (Pubitemid 41128663)
12. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395-1401. (Pubitemid 43772272)
13. Bellmunt Molins J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU) [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 5028.
14. World Health Organization. WHO Handbook for Reporting of Cancer Treatment. World Health Organization Offset Pub. No.48. Geneva, Switzerland: World Health Organziation; 1979.
15. Bennouna J, Campone M, Delord JP, et al. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs. 2005;14:1259-1267. (Pubitemid 41488874)